Pfizer/BioNTech COVID-19 vaccine effectiveness drops after 6 months -study


The analysis showed that the vaccine's effectiveness in preventing hospitalization and death remained high at 90% for at least six months, even against the highly contagious Delta variant of the coronavirus. The data suggests that the drop is due to waning efficacy, rather than more contagious variants, researchers said.

The effectiveness of the Pfizer Inc/BioNTech SE vaccine in preventing infection by the coronavirus dropped to 47% from 88% six months after the second dose, according to data published on Monday that U.S. health agencies considered when deciding on the need for booster shots.

The data, which was published in the Lancet published medical journal, had been previously released in August ahead of peer review.

Limited time offer:
Just RM5 per month.

Monthly Plan

RM13.90/month
RM5/month

Billed as RM5/month for the 1st 6 months then RM13.90 thereafters.

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Pfizer , Biontech , vaccine , third shot , effcacy ,

   

Next In Business News

Martijn Rene van Keulen to helm Heineken Malaysia from July 1
OCK proposed RM500mil ICP programme
Profit-taking in the market, KLCI down 0.14%
EPF balancing between retirement mandate and supporting members' economic survival
Asian stocks hit by US tech slide, FX subdued
CelcomDigi emphasises its significant role in protecting customers from AI-related risks
China's largest auto show showcases all-electric future, local brands dominate
Unilever beats first quarter sales forecasts, sticks to 2024 outlook
Oil steady as market weighs US demand concerns, Middle East conflict risks
HeiTech Padu targets stronger earnings growth after returning to black in 2023

Others Also Read